Patents by Inventor Michael J. Dey
Michael J. Dey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8748382Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: April 3, 2012Date of Patent: June 10, 2014Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Publication number: 20130157955Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: ApplicationFiled: April 3, 2012Publication date: June 20, 2013Applicants: Ipsen Pharma S.A.S., Radius Health, Inc.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Patent number: 8148333Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: October 3, 2007Date of Patent: April 3, 2012Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Publication number: 20110092425Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: ApplicationFiled: August 12, 2010Publication date: April 21, 2011Applicants: Radius Health, Inc., Ipsen Pharma S.A.SInventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Patent number: 7803770Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: May 9, 2008Date of Patent: September 28, 2010Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Publication number: 20100029556Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: ApplicationFiled: October 3, 2007Publication date: February 4, 2010Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Publication number: 20090227498Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: ApplicationFiled: May 9, 2008Publication date: September 10, 2009Applicant: Radius Health, Inc.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Patent number: 5209933Abstract: There is disclosed an improved long acting sustained release pharmaceutical composition for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binder, which are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter, are provided with a coating to obtain slow, sustained release of a safe, therapeutically effective amount of the calcium channel blocker over a period of at least about 24 hours. Thus, the improved pharmaceutical composition for a dihydropyridine calcium channel blockers is suitable for once daily administration.Type: GrantFiled: September 13, 1991Date of Patent: May 11, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Calum B. MacFarlane, Alastair B. Selkirk, John R. Langridge, Michael J. Dey
-
Patent number: 5198226Abstract: A long acting sustained release pharmaceutical composition for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binder are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter.Type: GrantFiled: November 12, 1991Date of Patent: March 30, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Calum B. MacFarlane, Alastair B. Selkirk, Michael J. Dey
-
Patent number: 5164405Abstract: There is disclosed a stable pharmaceutical composition containing nicardipine hydrochloride, a non-chloride isotonicity agent, a buffering agent and a pharmaceutically acceptable aqueous vehicle for parenteral administration.Type: GrantFiled: October 22, 1990Date of Patent: November 17, 1992Assignee: Syntex (U.S.A.) Inc.Inventors: Calum B. McFarlane, Alistair B. Selkirk, Michael J. Dey
-
Patent number: 5063220Abstract: A pharmaceutical formulation suitable for parenteral (preferably intravenous) administration includes an effective amount of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]p iperazine and a suitable amount of an acid to generate a pharmaceutically acceptable salt having a pH above about 3.0 and a solubility above about 4.0 mg/ml. The intravenous formulation optionally includes a suitable tonicifier in a quantity sufficient to achieve isotonicity with body fluids. The salt is formed in situ during the formulation process. The salt of tartaric acid is preferred; suitable salts for lower concentration dosages are the citric acid and methane sulphonic acid salts.Type: GrantFiled: September 20, 1990Date of Patent: November 5, 1991Assignee: Syntex Pharmaceuticals, Ltd.Inventors: Alastair B. Selkirk, Michael J. Dey
-
Patent number: 4973591Abstract: A pharmaceutical formulation suitable for parenteral (preferably intravenous) adminstration includes an effective amount of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]p iperazine and a suitable amount of an acid to generate a pharmaceutically acceptable salt having a pH above about 3.0 and a solubility above about 4.0 mg/ml. The intravenous formulation optionally includes a suitable tonicifier in a quantity sufficient to achieve isotonicity with body fluids. The salt is formed in situ during the formulation process. The slat of tartaric acid is preferred; suitable salts for lower concentration dosages are the citric acid and methane sulphonic acid salts.Type: GrantFiled: October 21, 1988Date of Patent: November 27, 1990Assignee: Syntex Pharmaceuticals, Ltd.Inventors: Alastair B. Selkirk, Michael J. Dey
-
Patent number: 4940556Abstract: A long acting sustained release pharmaceutical composition for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binde are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter.Type: GrantFiled: July 26, 1987Date of Patent: July 10, 1990Assignee: Syntex (U.S.A.) Inc.Inventors: Calum B. MacFarlane, Alastair B. Selkirk, Michael J. Dey
-
Patent number: RE49444Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: December 24, 2020Date of Patent: March 7, 2023Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle, Zhengxin Dong